15
May

Shares of Cambridge, MA-based bluebird bio shot up after CEO Nick Leschly noted the looming arrival of early-stage data for its drug LentiGlobin, designed to treat the rare blood disorder beta thalassemia.

…read more

Source: Bluebird bio buoyed by news of looming trial data

    

0 No comments